article thumbnail

Grifols’ Innovation Strategy in the Plasma Medicine Space

XTalks

Our pipeline, for example, includes a new class of recombinant antibodies. Within the next few months we’re expecting topline results from a Phase III clinical trial on a next-generation fibrinogen, an important plasma protein essential for blood clotting. What are key pipeline initiatives for Grifols in the coming years?

Medicine 111